Trial Profile
Patients outcomes in patients receiving delayed-release dimethyl fumarate treatment ≥ 12 months in Russia- findings from a real-world setting in Russian Federation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Oct 2018
Price :
$35
*
At a glance
- Drugs Dimethyl fumarate (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 29 Oct 2018 New trial record
- 12 Oct 2018 Results (data cut off: Apr 09, 2018) presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis